Abstract:Background: WHO issued the first edition catalogue of Mycobacterium tuberculosis complex (MTBC) mutations associated with drug resistance in 2021. However, country-specific issues might lead to arising complex and additional drug-resistant mutations. We aimed to fully reflect the characteristics of drug resistance mutations in China. Methods: We analysed MTBC isolates from the nationwide drug-resistant tuberculosis surveillance with 70 counties in 31 provinces, municipalities, and autonomous regions in China. Three types of MYCOTB plates were used to perform drug susceptibility testing for 12 antibiotics (rifampicin, isoniazid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid, delamanid, and bedaquiline). Mutations were divided into five groups according to their odds ratios, positive predictive values, false discovery rate-corrected p values, and 95% CIs: (1) associated with resistance; (2) associated with resistance-interim; (3) uncertain significance; (4) not associated with resistance-interim; and (5) not associated with resistance. The Wilcoxon rank-sum and Kruskal-Wallis tests were used to quantify the association between mutations and minimum inhibitory concentrations (MICs). Our dataset was compared with the first edition of the WHO catalogue. Findings: We analysed 10 146 MTBC isolates, of which 9071 (89·4%) isolates were included in the final analysis. 744 (8·2%) isolates were resistant to rifampicin and 1339 (14·8%) to isoniazid. 208 (1·9%) of 11 065 mutations were classified as associated with resistance or associated with resistance-interim. 33 (97·1%) of 34 mutations in group 1 and 92 (52·9%) of 174 in group 2 also appeared in groups 1 or 2 of the WHO catalogue. Of 81 indel mutations in group 2, 15 (18·5%) were in the WHO catalogue. The newly discovered mutation gyrA_Ala288Asp was associated with levofloxacin resistance. MIC values for rifampicin, isoniazid, moxifloxacin, and levofloxacin corresponding to resistance mutations in group 1 were significantly different (p<0·0001), and 12 high-level resistance mutations were detected. 61 mutations in group 3 occurred as solo in at least five phenotypically susceptible isolates, but with MIC values moderately higher than other susceptible isolates. Among 945 phenotypically resistant but genotypically susceptible isolates, 433 (45·8%) were mutated for at least one efflux pump gene. Interpretation: Our analysis reflects the complexity of drug resistance mutations in China and suggests that indel mutations, efflux pump genes, protein structure, and MICs should be fully considered in the WHO catalogue, especially in countries with a high tuberculosis burden. Funding: National Key Research and Development Program of China and the Science and Technology Major Project of Tibetan Autonomous Region of China.

Identification of Novel Mutations Associated with Cycloserine Resistance Inmycobacterium Tuberculosis

Molecular Basis Underlyingmycobacterium Tuberculosisd-Cycloserine Resistance. is There a Role for Ubiquinone and Meraquinone Metabolic Pathways?

Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and menaquinone metabolic pathways?

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis

Identification of drug resistance-related virulence gene mutations in 667 clinical Mycobacterium tuberculosis isolates

Comparative Genomic Analysis of Two Clonally Related Multidrug Resistant Mycobacterium tuberculosis by Single Molecule Real Time Sequencing

Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex

Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in <i>Mycobacterium tuberculosis</i>

Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India

Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

Genomic Sequence Based Scanning for Drug Resistance-Associated Mutations and Evolutionary Analysis of Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium Tuberculosis

Molecular Characterization of Drug-Resistant Mycobacterium Tuberculosis Isolates from Sichuan Province in China

Identification of Novel Mutations in LprG (rv1411c), Rv0521, Rv3630, Rv0010c, Ppsc, and Cyp128 Associated with Pyrazinoic Acid/Pyrazinamide Resistance in Mycobacterium Tuberculosis.

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

[The Effects of Gene Mutation Related to Drug Resistance and Drug Efflux Pump in Extensively Drug-Resistant Tuberculosis Clinical Isolates].

The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis